Sangamo Therapeutics (SGMO)

• Market cap: $73.6M
• 1 day: 31.56%
• 5 days: -13.74%
• 1 month: -36.25%
• 3 months: -50.69%
• 6 months: -68.38%
• Year to date: -59.51%
• 1 year: -75.33%
• 5 years: -98.44%
• 10 years: -96.83%
• Sector: Healthcare
• Industry: Biotechnology

About: Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its neurology development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases and development of novel engineered adeno-associated virus, or AAV, capsids to deliver its therapies to the intended neurological targets. The group's pipeline products are Small Fiber Neuropathy, Prion Disease, Tauopathies, ALS/FTD, Huntington's Disease, Fabry Disease, and Hemophilia A.

Employees: 142